About us

Empowering the future of medicine by integrating artificial intelligence and multiomics.

Our Technology

Our Technology

MAT a one-of-a-kind platform, is transforming medicine and technology alike. Uniquely designed from the ground up, it is the future of predictive healthcare, merging advanced neural networks and machine learning to simulate human systems biology.

This isn't just a mere evolution in technology, it's the birth of a new era.

MAT a one-of-a-kind platform, is transforming medicine and technology alike. Uniquely designed from the ground up, it is the future of predictive healthcare, merging advanced neural networks and machine learning to simulate human systems biology.

This isn't just a mere evolution in technology, it's the birth of a new era.

Our Expert Team

Our Expert Team

The Minds Behind the Innovation

The Minds Behind the Innovation

Meet the remarkable team steering GATC Health into the future. Our leadership is comprised of seasoned professionals from technology, science, and finance sectors.

Meet the remarkable team steering GATC Health into the future. Our leadership is comprised of seasoned professionals from technology, science, and finance sectors.

John Stroh

Chief Executive Officer

READ BIO

John Stroh

Chief Executive Officer

READ BIO

Jayson Uffens

Chief Technology Officer

READ BIO

Jayson Uffens

Chief Technology Officer

READ BIO

Jeff Moses

President

READ BIO

Jeff Moses

President

READ BIO

Ian Jenkins

Chief Science Officer

READ BIO

Ian Jenkins

Chief Science Officer

READ BIO

Tyrone Lam

Chief Business Officer

READ BIO

Tyrone Lam

Chief Business Officer

READ BIO

Vaishnavi Narayan

Principal AI Engineer

READ BIO

Vaishnavi Narayan

Principal AI Engineer

READ BIO

Eric J. Mathur

Chief Innovation Officer

READ BIO

Eric J. Mathur

Chief Innovation Officer

READ BIO

Gene O’Bryan

Chief Operating Officer

READ BIO

Gene O’Bryan

Chief Operating Officer

READ BIO

Jonathan Lakey, PhD, MSM

Chair of Scientific Advisory Board

READ BIO

Jonathan Lakey, PhD, MSM

Chair of Scientific Advisory Board

READ BIO

Michael Manahan

Chief Financial Officer

READ BIO

Michael Manahan

Chief Financial Officer

READ BIO

Waldemar Lernhardt, PhD

Vice President Scientific Operations

READ BIO

Waldemar Lernhardt, PhD

Vice President Scientific Operations

READ BIO

Robert Tinder, PhD

Head of Chemical Research

READ BIO

Robert Tinder, PhD

Head of Chemical Research

READ BIO

Saman Mirzaei, PhD

Senior Scientist

READ BIO

Saman Mirzaei, PhD

Senior Scientist

READ BIO

John Stroh

Chief Executive Officer

READ BIO

John Stroh

Chief Executive Officer

READ BIO

Jayson Uffens

Chief Technology Officer

READ BIO

Jayson Uffens

Chief Technology Officer

READ BIO

Ian Jenkins

Chief Science Officer

READ BIO

Ian Jenkins

Chief Science Officer

READ BIO

Jeff Moses

President

READ BIO

Jeff Moses

President

READ BIO

Robert Sorrentino, MD

Chief Medical Officer

READ BIO

Vaishnavi Narayan

Principle AI Engineer

READ BIO

Vaishnavi Narayan

Principle AI Engineer

READ BIO

Tyrone Lam

Chief Business Officer

READ BIO

Tyrone Lam

Chief Business Officer

READ BIO

Michael Manahan

Chief Financial Officer

READ BIO

Michael Manahan

Chief Financial Officer

READ BIO

Eric J. Mathur

Chief Innovation Officer

READ BIO

Eric J. Mathur

Chief Innovation Officer

READ BIO

Jonathan Lakey, PhD, MSM

Chair of Scientific Advisory Board

READ BIO

Jonathan Lakey, PhD, MSM

Chair of Scientific Advisory Board

READ BIO

Waldemar Lernhardt, PhD

Vice President Scientific Operations

READ BIO

Waldemar Lernhardt, PhD

Vice President Scientific Operations

READ BIO

Gene O’Bryan

Chief Operating Officer

READ BIO

Gene O’Bryan

Chief Operating Officer

READ BIO

Saman Mirzaei, PhD

Senior Scientist

READ BIO

Saman Mirzaei, PhD

Senior Scientist

READ BIO

Robert Tinder, PhD

Head of Chemical Research

READ BIO

Robert Tinder, PhD

Head of Chemical Research

READ BIO

  • Herb Boyer

    Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion

    I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.

  • Patrick Lilley

    CEO of Liquid Biosciences

    What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.

  • Lin Yu, PhD

    Former Managing Director Healthcare Investment Banking, Oppenheimer

    I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stake-holders in the healthcare community.

  • Tomas Philipson, PhD

    Former Acting Chairman of the White House Council of Economic Advisers

    I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.

  • Mark Palaima

    Former Chief Architect at eBay

    This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.

  • Herb Boyer

    Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion

    I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.

  • Patrick Lilley

    CEO of Liquid Biosciences

    What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.

  • Lin Yu, PhD

    Former Managing Director Healthcare Investment Banking, Oppenheimer

    I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stakeholders in the healthcare community.

  • Tomas Philipson

    Former Acting Chairman of the White House Council of Economic Advisers

    I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.

  • Mark Palaima

    Former Chief Architect at eBay

    This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.

  • Herb Boyer

    Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion

    I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.

  • Patrick Lilley

    CEO of Liquid Biosciences

    What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.

  • Lin Yu, PhD

    Former Managing Director Healthcare Investment Banking, Oppenheimer

    I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stakeholders in the healthcare community.

  • Tomas Philipson

    Former Acting Chairman of the White House Council of Economic Advisers

    I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.

  • Mark Palaima

    Former Chief Architect at eBay

    This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.

  • Herb Boyer

    Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion

    I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.

  • Patrick Lilley

    CEO of Liquid Biosciences

    What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.

  • Lin Yu, PhD

    Former Managing Director Healthcare Investment Banking, Oppenheimer

    I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stakeholders in the healthcare community.

  • Tomas Philipson

    Former Acting Chairman of the White House Council of Economic Advisers

    I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.

  • Mark Palaima

    Former Chief Architect at eBay

    This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.

Guiding Us Toward Excellence

Guiding Us Toward Excellence

Our Advisors and Mentors

Our Advisors and Mentors

Our board of advisors is a powerhouse of knowledge and experience. Comprising esteemed researchers, medical doctors, biotech executives, and policy experts, they offer invaluable guidance in steering GATC's mission.

Our board of advisors is a powerhouse of knowledge and experience. Comprising esteemed researchers, medical doctors, biotech executives, and policy experts, they offer invaluable guidance in steering GATC's mission.

  • Tomas Philipson, PhD

    Health Policy and Pharma Advisor

    READ BIO

    • Former Acting Chairman of the Council of Economic Advisers in the Trump administration

    • Former senior economic advisor to the head of the Food and Drug Association

    • Former senior economic advisor to the head of the Centers for Medicare & Medicaid Services

    • Professor of Public Policy Studies Emeritus at the Univ of Chicago Harris School of Public Policy

  • Chad Beyer, PhD

    Science Advisor

    READ BIO

    • 25 years of CNS drug discovery and development experience

    • 33 INDs; 70+ manuscripts; 2 blockbuster medications

    • NIDA; Wyeth; Ariel and Promentis Pharmaceuticals

  • John O'Reilly

    Health Policy Advisor

    READ BIO

    • Leader in healthcare, law, and business advisory.

    • Chairs UCLA Health System Board and University Medical Center of Southern Nevada.

    • Extensive experience in healthcare innovation and strategic planning.

    • Cum laude graduate in law and accounting, ex-military legal officer.

  • Dr. Jack Lewin

    Medical Advisor

    READ BIO

    • Administrator, Hawaii State Health Planning Development, Sr Advisor to Governor

    • Former CEO, American College of Cardiology, California Medical Assoc

    • Former President & CEO of Cardiovascular Research Foundation

  • Dr. Seema Gupta

    Medical Advisor

    READ BIO

    • Primary Care Physician with Veterans Administration (20 years).

    • Expert in Internal Medicine, Preventive Medicine, Public Health, Global Health.

    • Editorial Board of Internal Medicine Alerts (leading publication for medical providers).

  • Patrick Lilley

    Science Advisor

    READ BIO

    • CEO and Founder, Liquid Biosciences

    • Member Blockchain & AI Task Force

    • Inventor 75+ patents & trade secrets

    • Board Member, Mamogen, HepGene, LiquidLung

  • Mark Palaima

    Technology Advisor

    READ BIO

    • eBay—Chief Architect, Fellow—10 yrs.

    • Inkiru, Inc (Acquired by Walmart Labs)—Chief Scientist, Founder

    • Ismintis Systems —Founder

  • Dr. Stanley Lewis

    Medical Advisor

    READ BIO

    • Co-founder & CEO, A28 Therapeutics

    • Former Chief Medical Officer, Ansun Biopharma

    • Former Chief Medical Officer, TaliMed Biologics

  • Gerald P. Curatola, D.D.S.

    Business Development Advisor

    READ BIO

    • Internationally recognized biological doctor, inventor, author, and wellness pioneer

    • Adj. Clinical Associate Professor, New York University College of Dentistry

    • Founder of Rejuvenation Health, medical and dental practices, and Revitin Oral Care.

  • Dr. David Kushner

    Nuclear Radiology Specialist

    READ BIO

    • 35+ years as Nuclear Radiology Specialist / US Navy Physician

    • Fellow in Musculoskeletal imaging and Nuclear Medicine

    • Assistant professor at Uniform University of the Health Science

  • Herbert Boyer

    Science Advisor

    READ BIO

    • Co-founder Genentech (first biotech company to go public)

    • Co-discovered methods that founded genetic engineering.

    • Numerous awards including the Albert Lasker Award for Medical Research, Industrial Research Institute Achievement Award, the National Medal of Technology, National Medal of Science.

  • Richard Schatz, MD

    Chair of Medical Advisor Board

    READ BIO

    • Co-inventor of the coronary stent and international expert in interventional cardiology

    • Inducted into the National Academy of Inventors and won the prestigious Russ Prize for Bioengineering, considered the American Nobel Prize

    • Adjunct Professor of Medicine and Cardiology at Duke University

  • Lin Yu, PhD

    Board of Directors

    READ BIO

    • Former Managing Director Oppenheimer Healthcare Investment Banking

    • Former Managing Director at BTIG Healthcare Investment Banking

    • Ph.D. from Columbia University in chemical engineering focused on next-generation DNA sequencing technologies

  • Joseph Stauffer

    Medical Advisor

    READ BIO

    • CEO/Founder Alta Life Sciences, CMO Antibe Therapeutics, Chairman BioFuse Medical Technologies

    • Former Assistant Professor John Hopkins Medicine, FDA Medical Officer, Global Medical Director for Abbott Labs, U.S. Navy Medical.

  • Jayson Hymes

    Medical Advisor

    READ BIO

    • Fellow of the American College of Pain Medicine, Fellow of the American Society of Addiction Medicine, Assistant Clinical Professor Anesthesiology & Pain Medicine at USC School of Medicine

    • Former advisor to Office of National Drug Control Policy, the Medical Board of California, California Narcotics Officers Association, Los Angeles Field Division of the DEA.

  • Tomas Philipson, PhD

    Health Policy and Pharma Advisor

    READ BIO

    • Former Acting Chairman of the Council of Economic Advisers in the Trump administration

    • Former senior economic advisor to the head of the Food and Drug Association

    • Former senior economic advisor to the head of the Centers for Medicare & Medicaid Services

    • Professor of Public Policy Studies Emeritus at the Univ of Chicago Harris School of Public Policy

  • Chad Beyer, PhD

    Science Advisor

    READ BIO

    • 25 years of CNS drug discovery and development experience

    • 33 INDs; 70+ manuscripts; 2 blockbuster medications

    • NIDA; Wyeth; Ariel and Promentis Pharmaceuticals

  • John O'Reilly

    Health Policy Advisor

    READ BIO

    • Leader in healthcare, law, and business advisory.

    • Chairs UCLA Health System Board and University Medical Center of Southern Nevada.

    • Extensive experience in healthcare innovation and strategic planning.

    • Cum laude graduate in law and accounting, ex-military legal officer.

  • Dr. Jack Lewin

    Medical Advisor

    READ BIO

    • Administrator, Hawaii State Health Planning Development, Sr Advisor to Governor

    • Former CEO, American College of Cardiology, California Medical Assoc

    • Former President & CEO of Cardiovascular Research Foundation